Clinical trials for the treatment of prostate cancer
Before the Q-PRO® system can be commercialized, the treatment must be proven to be effective, safe, and to deliver the intended clinical benefit. We currently have two ongoing clinical studies for patients with prostate cancer, conducted by leading physicians at top prostate cancer centres in North America and Europe. The first study focuses on patients with recurrent prostate cancer, while the second study is aimed at the primary treatment of localized prostate cancer.
University College London Hospital
Memorial Sloan Kettering Cancer Center
Princess Margaret Cancer Center
Skånes universitetssjukhus
The goal of the trials
The goal of the trials is to investigate the effect of the treatment, to determine the optimal dose of laser light and drug and to investigate how safe the use of laser treatment in combination with the medicinal substance verteporfin is.
Trial for prostate cancer recurrence
We follow a clear development strategy and have initially started a clinical trial for patients who have relapsed from prostate cancer, after previously undergoing radiotherapy. The clinical trial is carried out by prominent doctors at leading prostate cancer clinics: Princess Margaret Cancer Center in Toronto, University College London Hospital, Memorial Sloan Kettering Cancer Center in New York and at Skåne University Hospital in Malmö. Through leading doctors and reference clinics, SpectraCure builds important clinical evidence to gain acceptance for the treatment in the future.
Trial for primary localised prostate cancer
The second study is aimed at patients with previously untreated, intermediate-risk prostate cancer. This new study broadens the recruitment base and addresses a significantly larger market. The study is being conducted in parallel with the first study in rec urrent prostate cancer. The recurrent prostate cancer study has been strategically important in the planning of the study for primary localized prostate cancer. To date, the study has been initiated at Memorial Sloan Kettering Cancer Center in New York and at the University Hospital in Cologne.